We conducted a retrospective cohort study in an attempt to re-evaluate the clinical significance of variceal bleeding. Methods: A cohort of 304 patients with liver cirrhosis and esophageal varices ...

If its efficacy is confirmed, it may permit institution of prophylactic measures like beta-adrenergic antagonists for preventing primary variceal bleeding in patients with liver cirrhosis ...

As cirrhosis progresses, patients may experience a range of symptoms including jaundice (yellowing of the skin and eyes), ascites (accumulation of fluid in the abdomen), variceal bleeding (due to ...

Gastric variceal hemorrhage is a serious consequence of end-stage liver disease, which is associated with high morbidity and mortality. 1 The majority of patients with cirrhosis develop varices ...

which shows that the drug decreases portal hypertension and improves liver perfusion in patients with cirrhosis. Complications of portal hypertension include the development of esophageal varices ...

In view of his existing infectious conditions, hepatic cirrhosis was suspected as the cause of his bleeding from esophageal varices ... arise in the absence of liver cirrhosis.

Title: In patients with compensated MASH cirrhosis with platelet count 150,000/µL and radiologic findings of portal hypertension, a third are identified with esophageal varices on screening ...

Cirrhosis is a progressive liver condition that often remains hidden in its early stages. The disease, marked by irreversible ...

Should cirrhosis, which is the most advanced form of liver disease, develop, you might notice more pronounced symptoms such as a yellow tint to your skin and eyes (referred to as jaundice), itchy ...

There is a growing global burden of liver disease with the current management for complications of liver cirrhosis being reactive as opposed to proactive, affecting outcomes. Management can often be ...

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...

Galectin Therapeutics (GALT) announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and ...